Abcellera Biologics Inc
F:8QQ
Abcellera Biologics Inc
F:8QQ
Price:
3.13
EUR
0.84%
Market Cap:
€920.4m
Income Statement
Earnings Waterfall
Abcellera Biologics Inc
Abcellera Biologics Inc
Income Statement
Abcellera Biologics Inc
Abcellera Biologics Inc
Currency: USD
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
5
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
422
N/A
|
438
+4%
|
444
+1%
|
375
-15%
|
489
+30%
|
507
+4%
|
603
+19%
|
485
-20%
|
181
-63%
|
145
-20%
|
50
-65%
|
38
-25%
|
36
-6%
|
33
-8%
|
33
0%
|
29
-13%
|
23
-20%
|
33
+42%
|
35
+7%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(104)
|
(127)
|
(160)
|
(171)
|
(218)
|
(237)
|
(267)
|
(269)
|
(254)
|
(261)
|
(259)
|
(275)
|
(263)
|
(302)
|
(341)
|
(344)
|
(346)
|
(312)
|
(297)
|
|
| Selling, General & Administrative |
(19)
|
(30)
|
(42)
|
(49)
|
(56)
|
(61)
|
(66)
|
(67)
|
(69)
|
(71)
|
(72)
|
(75)
|
(77)
|
(81)
|
(85)
|
(85)
|
(84)
|
(83)
|
(85)
|
|
| Research & Development |
(30)
|
(36)
|
(54)
|
(62)
|
(76)
|
(88)
|
(97)
|
(108)
|
(134)
|
(144)
|
(155)
|
(176)
|
(162)
|
(167)
|
(170)
|
(167)
|
(170)
|
(169)
|
(183)
|
|
| Depreciation & Amortization |
(5)
|
(8)
|
(11)
|
(15)
|
(15)
|
(17)
|
(18)
|
(28)
|
(29)
|
(30)
|
(31)
|
(24)
|
(24)
|
(55)
|
(86)
|
(91)
|
(91)
|
(60)
|
(29)
|
|
| Other Operating Expenses |
(50)
|
(53)
|
(53)
|
(46)
|
(70)
|
(72)
|
(87)
|
(66)
|
(22)
|
(17)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
318
N/A
|
312
-2%
|
284
-9%
|
204
-28%
|
272
+33%
|
270
-1%
|
336
+24%
|
217
-36%
|
(73)
N/A
|
(116)
-59%
|
(209)
-80%
|
(237)
-13%
|
(227)
+4%
|
(269)
-19%
|
(308)
-14%
|
(315)
-2%
|
(323)
-2%
|
(279)
+14%
|
(261)
+6%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
(4)
|
(2)
|
0
|
(3)
|
(0)
|
0
|
0
|
12
|
22
|
33
|
43
|
46
|
47
|
46
|
45
|
56
|
54
|
51
|
48
|
|
| Total Other Income |
10
|
6
|
7
|
18
|
18
|
15
|
21
|
11
|
12
|
13
|
9
|
17
|
12
|
45
|
61
|
58
|
58
|
29
|
8
|
|
| Pre-Tax Income |
324
N/A
|
315
-3%
|
290
-8%
|
219
-25%
|
288
+32%
|
284
-2%
|
355
+25%
|
239
-33%
|
(40)
N/A
|
(71)
-78%
|
(157)
-121%
|
(174)
-11%
|
(169)
+3%
|
(179)
-6%
|
(202)
-13%
|
(200)
+1%
|
(211)
-5%
|
(199)
+6%
|
(205)
-3%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(83)
|
(84)
|
(80)
|
(66)
|
(84)
|
(83)
|
(107)
|
(81)
|
(10)
|
(3)
|
28
|
28
|
22
|
26
|
26
|
38
|
43
|
33
|
33
|
|
| Income from Continuing Operations |
241
|
232
|
211
|
154
|
205
|
200
|
248
|
159
|
(50)
|
(74)
|
(129)
|
(146)
|
(147)
|
(153)
|
(176)
|
(163)
|
(168)
|
(166)
|
(172)
|
|
| Net Income (Common) |
241
N/A
|
232
-4%
|
211
-9%
|
154
-27%
|
205
+33%
|
200
-2%
|
248
+24%
|
159
-36%
|
(50)
N/A
|
(74)
-47%
|
(129)
-75%
|
(146)
-13%
|
(147)
0%
|
(153)
-4%
|
(176)
-15%
|
(163)
+7%
|
(168)
-3%
|
(166)
+1%
|
(172)
-4%
|
|
| EPS (Diluted) |
0.75
N/A
|
0.85
+13%
|
0.75
-12%
|
0.48
-36%
|
0.65
+35%
|
0.7
+8%
|
0.8
+14%
|
0.5
-38%
|
-0.18
N/A
|
-0.27
-50%
|
-0.45
-67%
|
-0.51
-13%
|
-0.51
N/A
|
-0.53
-4%
|
-0.6
-13%
|
-0.55
+8%
|
-0.57
-4%
|
-0.56
+2%
|
-0.58
-4%
|
|
Switch to:
Switch to:
See Also
Discover More
